A lot of biotech attention goes to oncology, obesity, and rare disease, but cardiovascular disease is still one of the biggest markets in the sector. Reuters noted cardiovascular disease is one of the areas drawing buyer interest as pharma looks for assets that can offset patent cliffs.
That is why I think Cardiol’s positioning is more interesting than the market gives it credit for.
It is not trying to be another broad “platform” story with no near-term readout. It is focused on inflammation and fibrosis in heart disease, with recurrent pericarditis as the late-stage lead, myocarditis data already in hand, and CRD-38 pushing toward heart failure.
The heart failure angle is early, but strategically it makes sense. If the broader thesis is that inflammation-driven cardiac damage can be modified, then pericarditis and myocarditis are not the whole story. They are the proof points.
That is the kind of thing that can make a small biotech more than just one binary trial.